Oral contraceptives (OC) are among the most frequently used drugs in the world with approximately 100 million women worldwide taking OC. In contrast to the active controversy surrounding hormone replacement therapy, little attention has been focused on OC, a drug therapy taken by far more women for far longer time periods. We describe the population effects of current and long-term OC exposure on a prognostically well validated marker of arterial stiffness: carotid-femoral pulse wave velocity (PWV). The Asklepios study is a representative sample (2524 apparently healthy M/F volunteers, aged 35–55 years, 1301 women) from the Belgian general population, free from overt cardiovascular disease. The subjects were extensively screened (biochemistry, lifestyle, cardiac and vascular echography, arterial tonometry). PWV was measured from flow patterns registered by Doppler echography in the femoral and carotid arteries. Of 1301 women (median age 45.7 y), 27.4% were actively taking OC. In contrast past use of OC is far more prevalent with 81% of women having taken OC for at least 1 year. The median duration of exposition in these women was 13 years. Age-adjusted PWV was higher in women currently taking OC: 6.75 versus 6.55 m/s (difference 0.19 ± 0.09 m/s; p = 0.034). However, current OC users also had higher blood pressures (BP): systolic BP (+4.4 ± 0.9 mmHg; p < 0.001), diastolic BP (+2.3 ± 0.6 mmHg; p < 0.001). After adjustement for BP, the difference in PWV between current OC users and non-users became non-significant: 6.60 versus 6.62 m/s (difference 0.02 ± 0.09 m/s; p = 0.814). In contrast, duration of OC use is a significant determinant of PWV, even after adjustement for age, BP, lipid levels, body size, heart rate, drug therapy (lipid-lowering, antihypertensive), glycemic status and smoking: F = 6.1; p = 0.013. Per 10 years of OC exposure PWV increased by 0.1 m/s (0.02– 0.18; p = 0.013). Use of OC is associated with increased vascular stiffness in women. Current use is associated with increased PWV because OC’s increase blood pressure, long-term use (probably through structural remodelling of the vessels) is an independent determinant of PWV, increasing PWV by 0.10 m/s per 10 years exposure.
oral contraceptive arterial stiffness, birth control pill cardiovascular risk, long term oral contraceptive effects, pulse wave velocity contraception, hormonal contraception vascular health, oral contraceptive blood pressure, birth control pill side effects cardiovascular, arterial aging hormonal contraception
Cite this article
Rietzschel, E., De Buyzere, M., Segers, P., Bekaert, S., De Bacquer, D., De Backer, G., & Gillebert, T. (2008). Abstract 3002: Long Term Oral Contraceptive Use is an Independent Risk Factor for Arterial Stiffening. *Circulation*, *118*(suppl_18). https://doi.org/10.1161/circ.118.suppl_18.S_803-d
Rietzschel E, De Buyzere M, Segers P, Bekaert S, De Bacquer D, De Backer G, et al. Abstract 3002: Long Term Oral Contraceptive Use is an Independent Risk Factor for Arterial Stiffening. Circulation. 2008;118(suppl_18). doi:10.1161/circ.118.suppl_18.S_803-d
Rietzschel, E., et al. "Abstract 3002: Long Term Oral Contraceptive Use is an Independent Risk Factor for Arterial Stiffening." *Circulation*, vol. 118, no. suppl_18, 2008.
Norouzi V et al., 2011Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
Objective: Increased levels of homocysteine and C-reactive protein (CRP) are considered as independent risk factors for atherosclerosis. As the level of these factors is affected by sex hormones, a po...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side Effects
Yonis H et al., 2025
Open Access
BMJ (Clinical Research Ed.)
Objective: To evaluate the association between contemporary hormonal contraceptive use and the risk of incident ischaemic stroke and myocardial infarction.
Design: Real-world, nationwide, prospective ...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side EffectsGeneral OB/GYN > Epidemiology > Prevalence
Background: The combined hormonal contraceptive (CHC) with ethinylestradiol and progestins is the most widely used contraceptive method among young women and is used by millions worldwide. However, un...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side EffectsGeneral OB/GYN > Epidemiology > Prevalence
Huang Y et al., 2024
Open Access
Frontiers in Endocrinology
Background: Premature ovarian insufficiency/failure (POI/POF) is a significant issue for women of reproductive age. Anti-Müllerian hormone (AMH) is a potential biomarker of ovarian reserve, but its cl...
Contraception/Comparison > FABM vs Hormonal > Side EffectsContraception/Comparison > Side Effects > Hormonal ContraceptionGeneral OB/GYN > Epidemiology > Prevalence